File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis
Title | Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis |
---|---|
Authors | |
Issue Date | 1999 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com |
Citation | The 25th Annual Scientific Meeting of the American Society of Transplant Surgeons (ASTS), Chicago, IL., 19-21 May 1999. In Transplantation, 1999, v. 67 n. 9, p. S634 How to Cite? |
Abstract | PURPOSE: We studied the efficacy and safety of a nucleoside analogue lamivudine in prophylaxis against recurrent hepatitis B (HBV) in Asian patients after liver transplantation (LTx). METHODS: From September 1995 to September 1998, 27 Asian patients (age 17-60yr; M:F, 24:3) who were positive for HBsAg from chronic HBV underwent primary LTx using lamivudine prophylaxis. Ten (37%) patients were of UNOS status 1 and 6 (22%) had associated hepatocellular carcinoma. Fifteen patients received oral lamivudine (100 mg daily) for > 30 days (median, 90 days; 54-374 days) before LTx and 12 underwent LTx within 7 days (median, 4 days; 1-7 days) of lamivudine treatment. Sixteen patients were HBeAg-positive and 9 HBVDNA-positive (Quantiplex™ bDNA assay, Chiron Diagnostics) before lamivudine treatment. Six of 16 patients cleared HBeAg and 5 of 9 cleared HBVDNA before LTx. Lamivudine prophylaxis was continued after LTx and Hepatitis B immunoglobulin was not used. RESULTS: Five patients died of causes not related to HBV at 5 to 36 days after OLT. The remaining 22 (82%) patients were followed-up for a median of 15 months (4 to 39 months) after LTX. There was no adverse effect attributed to lamivudine. In 7 patients, HBsAg persisted or reappeared after a period of temporary clearance, and 15 patients remained HbsAg-negative at a median of 17 months after LTx. One (4.5%) patient developed recurrent hepatitis due to a mutant strain at the YMDD locus 397 days after LTx. There was no biochemical or histologic evidence of recurrent hepatitis B in the remaining 21 patients and none had detectable HBVDNA (by PCR) in serum at a median of 17 months (4 to 39 months) after LTx. CONCLUSIONS: At a median follow-up of 15 months, Lamivudine monotherapy is safe and effective in preventing recurrent hepatitis B following LTx in Asians. |
Description | Poster Presentation |
Persistent Identifier | http://hdl.handle.net/10722/101935 |
ISSN | 2023 Impact Factor: 5.3 2023 SCImago Journal Rankings: 1.371 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lo, CM | - |
dc.contributor.author | Fan, ST | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Liu, CL | - |
dc.contributor.author | Yuen, MF | - |
dc.contributor.author | Ng, IOL | - |
dc.contributor.author | Wong, J | - |
dc.date.accessioned | 2010-09-25T20:10:24Z | - |
dc.date.available | 2010-09-25T20:10:24Z | - |
dc.date.issued | 1999 | - |
dc.identifier.citation | The 25th Annual Scientific Meeting of the American Society of Transplant Surgeons (ASTS), Chicago, IL., 19-21 May 1999. In Transplantation, 1999, v. 67 n. 9, p. S634 | - |
dc.identifier.issn | 0041-1337 | - |
dc.identifier.uri | http://hdl.handle.net/10722/101935 | - |
dc.description | Poster Presentation | - |
dc.description.abstract | PURPOSE: We studied the efficacy and safety of a nucleoside analogue lamivudine in prophylaxis against recurrent hepatitis B (HBV) in Asian patients after liver transplantation (LTx). METHODS: From September 1995 to September 1998, 27 Asian patients (age 17-60yr; M:F, 24:3) who were positive for HBsAg from chronic HBV underwent primary LTx using lamivudine prophylaxis. Ten (37%) patients were of UNOS status 1 and 6 (22%) had associated hepatocellular carcinoma. Fifteen patients received oral lamivudine (100 mg daily) for > 30 days (median, 90 days; 54-374 days) before LTx and 12 underwent LTx within 7 days (median, 4 days; 1-7 days) of lamivudine treatment. Sixteen patients were HBeAg-positive and 9 HBVDNA-positive (Quantiplex™ bDNA assay, Chiron Diagnostics) before lamivudine treatment. Six of 16 patients cleared HBeAg and 5 of 9 cleared HBVDNA before LTx. Lamivudine prophylaxis was continued after LTx and Hepatitis B immunoglobulin was not used. RESULTS: Five patients died of causes not related to HBV at 5 to 36 days after OLT. The remaining 22 (82%) patients were followed-up for a median of 15 months (4 to 39 months) after LTX. There was no adverse effect attributed to lamivudine. In 7 patients, HBsAg persisted or reappeared after a period of temporary clearance, and 15 patients remained HbsAg-negative at a median of 17 months after LTx. One (4.5%) patient developed recurrent hepatitis due to a mutant strain at the YMDD locus 397 days after LTx. There was no biochemical or histologic evidence of recurrent hepatitis B in the remaining 21 patients and none had detectable HBVDNA (by PCR) in serum at a median of 17 months (4 to 39 months) after LTx. CONCLUSIONS: At a median follow-up of 15 months, Lamivudine monotherapy is safe and effective in preventing recurrent hepatitis B following LTx in Asians. | - |
dc.language | eng | - |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com | - |
dc.relation.ispartof | Transplantation | - |
dc.rights | This is a non-final version of an article published in final form in (provide complete journal citation) | - |
dc.title | Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Lo, CM: chungmlo@hku.hk | - |
dc.identifier.email | Fan, ST: stfan@hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hku.hk | - |
dc.identifier.email | Liu, CL: clliu@hkucc.hku.hk | - |
dc.identifier.email | Yuen, MF: mfyuen@hku.hk | - |
dc.identifier.email | Ng, IOL: iolng@hku.hk | - |
dc.identifier.email | Wong, J: jwong@hkucc.hku.hk | - |
dc.identifier.authority | Lo, CM=rp00412 | - |
dc.identifier.authority | Fan, ST=rp00355 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, MF=rp00479 | - |
dc.identifier.authority | Ng, IOL=rp00335 | - |
dc.identifier.authority | Wong, J=rp00322 | - |
dc.identifier.hkuros | 40649 | - |
dc.identifier.hkuros | 41177 | - |
dc.identifier.volume | 67 | - |
dc.identifier.issue | 9 | - |
dc.identifier.spage | S634 | - |
dc.identifier.epage | S634 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0041-1337 | - |